Hongli Group Inc.

Xell Energy completes product development and customer evaluation of ultra-high-energy-density 420 Wh/kg battery packs WEIFANG, China, Oct. 13, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold roll-formed steel profile manufacturer advancing its strategic transition into high-growth clean energy sectors, today provided a corporate update regarding its proposed strategic collaboration with Xell Energy, Inc. ("Xell Energy"). Xell Energy has completed product development and customer evaluation of its high-energy-density battery packs incorporating advanced battery cells with an energy density of up to 420 Wh/kg.

Helus Pharma remains a buy, as HLP003's Phase 3 APPROACH topline data in 4Q26 is the key near-term catalyst. HLP003 targets adjunctive MDD with a differentiated intermittent dosing model; prior Phase 2 data showed a 23-point MADRS reduction and 71% remission at 12 months. HELP's $166.4M cash balance provides 12–14 months runway, but dilution risk persists given high operating outflows and the $100M ATM facility.

WEIFANG, China, Oct. 5, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold roll formed steel profile manufacturer, today announced a leadership transition within its Board of Directors (the "Board"). Effective September 29, 2026, Mr.

Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen's Novel Mechanisms in Neuropsychiatry virtual summit.